Yu and his colleagues also showed us anti-CD40 agonist therapy could amplify immune-activated cDC1 subset, increase effector memory CD8+ CTLs, and induce the activation and expansion of TH1-like CD4+ T cells in MC38 tumor model [92]. This evidence concerns the gene CD4 and neoplasm.